

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Burosumab for treating X-linked hypophosphataemia in adults ID3822

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Kyowa Kirin (burosumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Brain and Spine Foundation • Brittle Bone Society • Findacure • Genetic Alliance UK • Metabolic Support UK • Pain Concern • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • STEPS • XLH UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Dental Association • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Society for Paediatric Endocrinology and Diabetes • British Society for Rehabilitation Medicine • Physiotherapy Pain Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • National Services Division • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Government <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • A A H Pharmaceuticals (alphacalcitriol) • Atnahs Pharma UK (calcitriol) • Sigma Pharmaceuticals (alphacalcitriol) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research

Provisional stakeholder list for the appraisal of burosumab for treating X-linked hypophosphataemia in adults ID3822 Issue date: January 2021

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> • Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital • Central Manchester University Hospitals NHS Foundation Trust, Metabolic Bone Disease Team • Leeds Teaching Hospitals NHS Trust • Northern General Hospital, Metabolic Bone Centre • Nuffield Orthopaedic Centre • Royal National Orthopaedic Hospital • University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre • University Hospitals Bristol, Rheumatology Department • University of Edinburgh Western General Hospital, Rheumatic Diseases Unit • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Orthopaedic Research UK • Pain Relief Foundation • Society of Back Pain Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the evaluation; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee